Anti-ανβ6 antibodies

Patent metadata

Field	Value
Publication number	US-9745376-B2
Application number	US-201414444701-A
Country	US
Kind code	B2
Filing date	Jul 28, 2014
Priority date	Mar 13, 2002
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

First claim

What is claimed is:

1. A DNA encoding a heavy chain of an anti-αvβ6 antibody or antigen-binding fragment thereof, the humanized heavy chain comprising a heavy chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 3, 6, and 9, respectively.

2. A DNA encoding a light chain of an anti-αvβ6 antibody or antigen-binding fragment thereof, the light chain comprising a light chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 12, 14, and 18, respectively.

3. A host cell producing an anti-αvβ6 antibody or antigen-binding fragment thereof, comprising:
a first DNA encoding a heavy chain of the anti-αvβ6 antibody or antigen-binding fragment thereof, the heavy chain comprising a heavy chain variable region comprising complementarity determining regions (CDRs) 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 3, 6, and 9, respectively; and
a second DNA encoding a light chain of the anti-αvβ6 antibody or antigen-binding fragment thereof, the light chain comprising a light chain variable region comprising CDRs 1, 2, and 3 consisting of the amino acid sequences set forth in SEQ ID NOs.: 12, 14, and 18, respectively.

4. The host cell of claim 3 , wherein the host cell is a CHO cell.

5. The host cell of claim 3 , wherein the host cell is an NSO cell.

6. A method of producing a soluble anti-αvβ6 antibody or antigen-binding fragment thereof, the method comprising culturing the host cell of claim 3 under conditions that produce the soluble anti-αvβ6 antibody or antigen-binding fragment thereof.

7. The method of claim 6 , wherein the host cell is a CHO cell.

8. The method of claim 6 , wherein the host cell is an NSO cell.

Assignees

• Biogen Ma Inc
• Univ California

Inventors

• Violette Shelia M
• Weinreb Paul Henry
• Simon Kenneth J
• Sheppard Dean
• Leone Diane R

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title